In Conversation

Singapore Pharma Report 2021
Latest Reports
Singapore Pharma Report 2021
- 2021
With outstanding fundamentals, including top-class universities and hospitals, a government cognizant of the benefits that a robust research-based biopharma industry brings, and straightforward business processes, Singapore has long been a hub for life science companies looking to penetrate the vast Asia-Pacific region. This exclusive new report deep dives into Singapore’s key attractions for international investors, from how its excellence in regulatory science has created a testbed for next-generation therapies and products, to the nation’s status as an advanced biomanufacturing hub for the region, to its increasing focus on translational research, building up an enabling ecosystem for biotechs seeking to…
China Pharma Report February 2020
Latest Reports
China Pharma Report February 2020
- 2020
This new issue of China Healthcare and Life Sciences Review (compiled in December 2019) provides a retrospective of the tremendous gains the Chinese healthcare industry made in 2019 while simultaneously anticipating the challenges and opportunities on the horizon in the new decade. From the steady national expansion of pilot regulatory reforms to the continuing exuberance of enterprising biotechs to the bold multidimensionality of multinationals’ investment in China, the report serves to recap the noteworthy advancements and positive trajectory of the Chinese healthcare sector even as the country pulls together to deal with the ongoing coronavirus crisis. China has dominated…
Taiwan Pharma Report November 2019
Latest Reports
Taiwan Pharma Report November 2019
- 2019
Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an enviable reputation at the forefront of some of the most innovative trends shaping global healthcare today.   From artificial intelligence to blockchain, the internet of things and regenerative medicine, Taiwanese firms – with the backing of an increasingly supportive research and funding ecosystem – are forging their way towards a disruptive future.
Thailand Pharma Report November 2019
Latest Reports
Thailand Pharma Report November 2019
- 2019
Thailand is in the midst of an economic transformation with healthcare at its heart. ASEAN’s second largest economy has implemented an ‘Industry 4.0’ policy through which it is attempting to prioritise R&D and innovation in a number of key industries, including healthcare and the life sciences.   Already a regional frontrunner in terms of the implementation of universal healthcare, Thailand is aiming to scale the value chain and grow its footprint in specific niches where it can excel, including clinical research and infectious disease vaccine production. The country is also aiming to cement its reputation as one of Asia’s…
China Pharma Report October 2019
Latest Reports
China Pharma Report October 2019
- 2019
With optimism and energy pervading the Chinese healthcare landscape, actors of all stripes see new potential and opportunities on the horizon. The heterogeneity of the Chinese market, with its 31 province-level entities offering a variety of market characteristics and needs; the waves of overseas returnees repatriating decades of experience in top pharma companies and biotechs, known as the so-called ‘sea turtles’; the budding capital markets unfurling their increasing interest in the sector; and the most pro-innovation regulatory environment the industry has seen practically since inception – all have coalesced into a veritable playground for the next generation of global…
Korea Pharma Report May 2019
Latest Reports
Korea Pharma Report May 2019
- 2019
One of the indisputable economic success stories of the last half century, South Korea now stands as the world’s 11th largest economy, with a reputation for industrial excellence and innovation. As the Korean state shifts its focus towards healthcare and the life sciences and Korean firms begin to internationalize with greater purpose, the attentions of the global investment community are being held evermore by a country that is thinking big.   This report covers the areas within the life sciences where Korea is garnering an increasingly strong international reputation, highlighting the country’s prowess in R&D and clinical trials, its…
China Pharma Report April 2019
Latest Reports
China Pharma Report April 2019
- 2019
China is the country it is impossible to ignore and now accounts for a significant share of revenues for most major multinational pharmaceutical companies. Further, any firm sincerely committed to bringing treatments to the greatest number of patients has to be active in China, whose population of 1.3 billion people makes up nearly a fifth of the world’s total.   This report examines the welter of healthcare reforms that have been rolled out over the past decade and the significant changes yet to come. It also looks at the biotech boom taking off in the country and the swathe…
Malaysia Pharma Report 2018
Latest Reports
Malaysia Pharma Report 2018
- 2018
Through exclusive interviews with the Malaysian Minister of Health as well as the head of the country’s regulatory body – the NPRA – this report examines emerging trends in Malaysian healthcare, with Prime Minister Matahir Mohamad spearheading a bold health policy reform. Also explored is the emergence of the halal medicine niche – where Malaysia has the potential to be a global leader given its geographic links to Southeast Asia and cultural ties to the Middle East – the first Malaysian biosimilars, the country’s outstanding potential as a regional clinical research hub and the rise of medical tourism.
Hong Kong Pharma Report 2018
Latest Reports
Hong Kong Pharma Report 2018
- 2018
Despite its small population size, Hong Kong has long held a strategic interest for the healthcare and life sciences industries, whether as a testbed for innovative products and service delivery models as a result of its efficient regulatory approval system or as an incubator for start-up companies looking to penetrate both mainland Chinese and international markets.   This report features the insights of biotech executives, research scientists, government representatives and the affiliate managers of some of the world’s largest and most innovative pharmaceutical companies who highlight the importance of a national framework for the development of the healthcare and…
Greater Bay Area Pharma Report
Latest Reports
Greater Bay Area Pharma Report
- 2018

Focus on South Korea

Read more from South Korea >>

Focus on Hong Kong

Read more from Hong Kong >>

Focus on Japan

Read more from Japan >>

Focus on Singapore

Read more from Singapore >>

Focus on Taiwan

Read more from Taiwan >>

Focus on China

Read more from China >>

We use cookies to ensure that we give you the best experience on our site. For more info click here